包含锚的药效学搜索,对受体结合贡献高于平均水平的片段,结合一步合成是快速发现新型生物活性分子的有力方法。在这里,我们展示了一条用于快速有效地发现天冬氨酰蛋白酶抑制剂的管道。首先,我们假设肼可能是与活性位点 Asp 羧酸相互作用的多价弹头。我们将肼锚定在多组分反应中,并创建了一个大型的肼衍生物虚拟库,可一步合成获得。接下来,我们对文库进行了基于锚定的药效团筛选,并重新合成了排名靠前的化合物。分子的抑制效力最终通过酶活性测定进行评估,结合模式由几种浸泡的晶体结构证实,支持假设和方法的有效性。本文报道的工具管道对于快速生成除 Asp 蛋白酶之外的受体结合剂具有普遍价值。
advantages of our methodology include an increased synthesis speed, very mild conditions giving access to hitherto unknown or highly reactive classes of isocyanides, rapid access to large numbers of functionalized isocyanides, increased yields, high purity, proven scalability over 5 orders of magnitude, increased safety and less reaction waste resulting in a highly reduced environmental footprint. For example
Combining High‐Throughput Synthesis and High‐Throughput Protein Crystallography for Accelerated Hit Identification
作者:Fandi Sutanto、Shabnam Shaabani、Rick Oerlemans、Deniz Eris、Pravin Patil、Mojgan Hadian、Meitian Wang、May Elizabeth Sharpe、Matthew R. Groves、Alexander Dömling
DOI:10.1002/anie.202105584
日期:2021.8.9
mmol scale synthesis on 96-well format and on a high-throughput nanoscale format in a highly automated fashion. High-throughput PX of our libraries efficiently yielded potent covalent inhibitors of the main protease of the COVID-19 causing agent, SARS-CoV-2. Our results demonstrate, that the marriage of in situ HT synthesis of (covalent) libraires and HT PX has the potential to accelerate hit finding
miniaturized and accelerated synthesis for efficient property optimization is a formidable challenge for chemistry in the 21st century as it helps to reduce resources and waste and can deliver products in shorter time frames. Here, we used for the first-time acoustic droplet ejection (ADE) technology and fast quality control to screen efficiency of synthetic reactions on a nanomole scale in an automated
实现高效性能优化的自动化、小型化和加速合成是 21 世纪化学面临的巨大挑战,因为它有助于减少资源和浪费,并可以在更短的时间内交付产品。在这里,我们首次使用声学液滴喷射(ADE)技术和快速质量控制,以自动化和小型化的方式筛选纳摩尔级合成反应的效率。中断的费歇尔吲哚与 Ugi 型反应相结合,产生了几种有吸引力的药物样支架。在 384 孔板中,产生了一组不同的间断 Fischer 吲哚中间体,并通过两步序列与三环乙内酰脲骨架反应。同样,预制的 Fischer 吲哚中间体用于生产多种 Ugi 产品,并将效率与原位方法进行了比较。在制备毫摩尔规模上重新合成了多个反应,显示出从纳米到毫克的可扩展性,从而显示出合成实用性。前所未有的大量建筑被用于快速范围和限制研究(68 种异氰化物,72 种羧酸)。生成的大合成数据的小型化和分析使得能够更深入地探索化学空间,并获得以前不切实际或不可能的知识,例如反应、结构单元和官能团兼容性的快速调查。
Modulators of TNF-alpha signaling
申请人:Genzyme Corporation
公开号:US20020119988A1
公开(公告)日:2002-08-29
The present invention provides compounds which are modulators of TNF-&agr; signaling and methods of use thereof for treating a patient having a TNF-&agr; mediated condition. The compounds can be represented by the following structural formulas:
1
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors
作者:Naoya Kitamura、Michael Dominic Sacco、Chunlong Ma、Yanmei Hu、Julia Alma Townsend、Xiangzhi Meng、Fushun Zhang、Xiujun Zhang、Mandy Ba、Tommy Szeto、Adis Kukuljac、Michael Thomas Marty、David Schultz、Sara Cherry、Yan Xiang、Yu Chen、Jun Wang
DOI:10.1021/acs.jmedchem.1c00509
日期:2022.2.24
Mpro inhibitor GC376. Significantly, 23R is highly selective compared with covalent inhibitors such as GC376, especially toward host proteases. The cocrystal structure of SARS-CoV-2 Mpro with 23R revealed a previously unexplored bindingsite located in between the S2 and S4 pockets. Overall, this study discovered 23R, one of the most potent and selective noncovalent SARS-CoV-2 Mpro inhibitors reported
SARS-CoV-2 的主要蛋白酶 (M pro ) 是经过验证的抗病毒药物靶点。据报道,几种 M pro抑制剂具有有效的酶抑制和细胞抗病毒活性,包括GC376 、 boceprevir 、钙蛋白酶抑制剂 II和XII ,每种抑制剂都含有共价修饰催化 Cys145 的反应弹头。将基于结构的药物设计与一锅 Ugi 四组分反应相结合,我们发现了最有效的非共价抑制剂之一23R ( Jun8-76-3A ),其结构与典型的 M pro抑制剂GC376不同。值得注意的是,与GC376等共价抑制剂相比, 23R具有高度选择性,尤其是针对宿主蛋白酶。 SARS-CoV-2 M pro与23R的共晶结构揭示了位于 S2 和 S4 口袋之间的先前未探索的结合位点。总体而言,这项研究发现了23R ,这是迄今为止报道的最有效和选择性最强的非共价 SARS-CoV-2 M pro抑制剂之一,以及 M pro中的一个新的结合口袋,可用于抑制剂设计。